PL2490712T3 - Sposób leczenia choroby Alzheimera przy zastosowaniu chaperonów farmakologicznych dla zwiększenia aktywności gangliozydaz - Google Patents
Sposób leczenia choroby Alzheimera przy zastosowaniu chaperonów farmakologicznych dla zwiększenia aktywności gangliozydazInfo
- Publication number
- PL2490712T3 PL2490712T3 PL10825421T PL10825421T PL2490712T3 PL 2490712 T3 PL2490712 T3 PL 2490712T3 PL 10825421 T PL10825421 T PL 10825421T PL 10825421 T PL10825421 T PL 10825421T PL 2490712 T3 PL2490712 T3 PL 2490712T3
- Authority
- PL
- Poland
- Prior art keywords
- gangliosidases
- disease
- activity
- increase
- treating alzheimer
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 102000005431 Molecular Chaperones Human genes 0.000 title 1
- 108010006519 Molecular Chaperones Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000000144 pharmacologic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25279909P | 2009-10-19 | 2009-10-19 | |
| EP10825421.0A EP2490712B1 (en) | 2009-10-19 | 2010-10-12 | Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases |
| PCT/US2010/052351 WO2011049787A1 (en) | 2009-10-19 | 2010-10-12 | Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2490712T3 true PL2490712T3 (pl) | 2015-12-31 |
Family
ID=43900619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10825421T PL2490712T3 (pl) | 2009-10-19 | 2010-10-12 | Sposób leczenia choroby Alzheimera przy zastosowaniu chaperonów farmakologicznych dla zwiększenia aktywności gangliozydaz |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9044437B2 (pl) |
| EP (2) | EP2957295B1 (pl) |
| JP (2) | JP6061677B2 (pl) |
| CA (1) | CA2778049C (pl) |
| DK (1) | DK2490712T3 (pl) |
| ES (2) | ES2646099T3 (pl) |
| PL (1) | PL2490712T3 (pl) |
| PT (1) | PT2490712E (pl) |
| WO (1) | WO2011049787A1 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101880411B1 (ko) * | 2009-10-19 | 2018-07-19 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 중추신경계의 퇴행성 질환을 예방 및/또는 치료하는 신규 조성물 |
| HUE037829T2 (hu) | 2011-08-31 | 2018-09-28 | St Jude Childrens Res Hospital | Eljárások és készítmények lizoszomális exocitózis aktivitás mértékének detektálására és alkamazási eljárások |
| ES2924829T3 (es) * | 2012-03-27 | 2022-10-11 | Amicus Therapeutics Inc | Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosómicas y/o trastornos degenerativos del sistema nervioso central |
| US9675627B2 (en) | 2014-04-14 | 2017-06-13 | Amicus Therapeutics, Inc. | Dosing regimens for treating and/or preventing cerebral amyloidoses |
| US10179128B2 (en) * | 2015-08-31 | 2019-01-15 | Amicus Therapeutics, Inc. | Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system |
| US9994589B2 (en) | 2015-12-14 | 2018-06-12 | Amicus Therapeutics, Inc. | Compounds and methods for the treatment of alzheimer's disease and/or cerebral amyloid angiopathy |
| WO2019132004A1 (ja) * | 2017-12-28 | 2019-07-04 | 国立大学法人熊本大学 | アルツハイマー病予防剤又は治療剤、そのスクリーニング方法、及びアルツハイマー病予防用又は治療用組成物 |
| US20240043373A1 (en) * | 2020-08-28 | 2024-02-08 | The Regents Of The University Of California | Compositions and methods for treating amyloid-related conditions |
| JP2024526764A (ja) * | 2021-07-13 | 2024-07-19 | トゥルーバインディング，インコーポレイテッド | タンパク質凝集を防止する方法 |
| CN116159129A (zh) * | 2023-03-29 | 2023-05-26 | 南通大学 | 唾液酸酶3或其活性片段在制备治疗阿尔茨海默病药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766846A (en) | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20070066543A1 (en) | 2003-05-22 | 2007-03-22 | The Hospital For Sick Children | Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity |
| MX2007015602A (es) * | 2005-06-08 | 2008-02-21 | Amicus Therapeutics Inc | Tratamiento de trastornos del sistema nervioso central asociados con mutaciones en genes que codifican las enzimas lisosomicas. |
| JP5303458B2 (ja) * | 2006-06-23 | 2013-10-02 | アミークス セラピューティックス インコーポレイテッド | β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法 |
| MX2009011473A (es) * | 2007-04-26 | 2010-01-18 | Amicus Therapeutics Inc | Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas. |
| WO2011011181A1 (en) | 2009-07-01 | 2011-01-27 | Amicus Therapeutics, Inc. | Pharmacological chaperones for the treatment of alzheimer's disease |
| US9675627B2 (en) * | 2014-04-14 | 2017-06-13 | Amicus Therapeutics, Inc. | Dosing regimens for treating and/or preventing cerebral amyloidoses |
-
2010
- 2010-10-12 PL PL10825421T patent/PL2490712T3/pl unknown
- 2010-10-12 WO PCT/US2010/052351 patent/WO2011049787A1/en not_active Ceased
- 2010-10-12 EP EP15173518.0A patent/EP2957295B1/en not_active Not-in-force
- 2010-10-12 EP EP10825421.0A patent/EP2490712B1/en not_active Not-in-force
- 2010-10-12 DK DK10825421.0T patent/DK2490712T3/en active
- 2010-10-12 ES ES15173518.0T patent/ES2646099T3/es active Active
- 2010-10-12 CA CA2778049A patent/CA2778049C/en not_active Expired - Fee Related
- 2010-10-12 US US13/501,586 patent/US9044437B2/en active Active
- 2010-10-12 ES ES10825421.0T patent/ES2549504T3/es active Active
- 2010-10-12 PT PT108254210T patent/PT2490712E/pt unknown
- 2010-10-12 JP JP2012535238A patent/JP6061677B2/ja not_active Expired - Fee Related
-
2015
- 2015-05-05 US US14/704,445 patent/US9931353B2/en active Active
- 2015-11-09 JP JP2015219607A patent/JP6204961B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HK1215534A1 (en) | 2016-09-02 |
| EP2957295A1 (en) | 2015-12-23 |
| US9044437B2 (en) | 2015-06-02 |
| HK1175400A1 (zh) | 2013-07-05 |
| EP2490712B1 (en) | 2015-07-08 |
| PT2490712E (pt) | 2015-10-27 |
| JP6204961B2 (ja) | 2017-09-27 |
| EP2957295B1 (en) | 2017-08-02 |
| US9931353B2 (en) | 2018-04-03 |
| JP6061677B2 (ja) | 2017-01-18 |
| JP2016041741A (ja) | 2016-03-31 |
| US20150374733A1 (en) | 2015-12-31 |
| EP2490712A1 (en) | 2012-08-29 |
| JP2013508371A (ja) | 2013-03-07 |
| US20120309788A1 (en) | 2012-12-06 |
| ES2549504T3 (es) | 2015-10-28 |
| WO2011049787A1 (en) | 2011-04-28 |
| EP2490712A4 (en) | 2013-06-12 |
| DK2490712T3 (en) | 2015-10-05 |
| CA2778049A1 (en) | 2011-04-28 |
| ES2646099T3 (es) | 2017-12-12 |
| CA2778049C (en) | 2018-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2490712T3 (pl) | Sposób leczenia choroby Alzheimera przy zastosowaniu chaperonów farmakologicznych dla zwiększenia aktywności gangliozydaz | |
| IL219412A0 (en) | New therapeutic approaches for treating alzheimer disease | |
| EP2142197A4 (en) | PROCESS FOR THE TREATMENT OF FABRY DISEASE USING PHARMACOLOGICAL CHAPERONS | |
| IL216399A0 (en) | Pharmaceutical composition for the treatment of heart diseases | |
| PL3064206T3 (pl) | Leczenie choroby Huntingtona z zastosowaniem lakwinimodu | |
| EP2485733A4 (en) | METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| IL216967A0 (en) | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases | |
| PT2435825E (pt) | Métodos para o tratamento de doenças | |
| GB2496801B (en) | A method of treating alzheimer's disease | |
| ZA201109278B (en) | Method for treatment of diseases | |
| GB0904427D0 (en) | Treatment of diseases related to hyperactivity of the complement system | |
| PT3318881T (pt) | Processo para monitorizar a doença de gaucher | |
| ZA201108496B (en) | System for treatment of biomass to facilitate the production of ethanol | |
| EP2391379A4 (en) | COMPOUNDS AND METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER | |
| EP2413696A4 (en) | COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| GB0909575D0 (en) | Method of screening for agents to treat alzheimer's disease | |
| EP2613849A4 (en) | RADIATION THERAPY FOR THE TREATMENT OF MORBUS ALZHEIMER | |
| GB0816956D0 (en) | Method of screening for agents to treat alzheimer's disease | |
| GB0812780D0 (en) | Method of screening for agents to treat alzheimer's disease | |
| GB0812779D0 (en) | Method of screening for agents to treat alzheimer's disease | |
| GB0915893D0 (en) | Method of screening for agents to treat Alzheimer's Disease | |
| GB0811555D0 (en) | Treatment of Alzheimer's disease | |
| GB0904178D0 (en) | General cure to diseases idea 3 |